Sanofi Medley Farmacêutica Ltda. Sustainability Profile
Sanofi Medley Farmacêutica Ltda., a prominent player in the pharmaceutical industry, is headquartered in Brazil and operates extensively across Latin America. Founded in 2001, the company has established itself as a leader in the development and distribution of innovative healthcare solutions, focusing on prescription medicines, vaccines, and consumer healthcare products. With a commitment to improving patient outcomes, Sanofi Medley offers a diverse portfolio that includes treatments for chronic diseases, rare conditions, and vaccines that address public health needs. The company is recognised for its dedication to research and development, which has led to significant advancements in therapeutic areas such as diabetes, oncology, and cardiovascular health. Sanofi Medley’s strategic position in the market is underscored by its robust distribution network and partnerships, enabling it to reach a wide range of healthcare providers and patients. Through its ongoing efforts, the company continues to make a meaningful impact on healthcare in Brazil and beyond.
DitchCarbon Score
How does Sanofi Medley Farmacêutica Ltda.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sanofi Medley Farmacêutica Ltda.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sanofi Medley Farmacêutica Ltda., headquartered in Brazil, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sanofi, and as such, it inherits climate commitments and performance metrics from its parent organisation. Sanofi has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded to Sanofi Medley Farmacêutica Ltda. at a level 1 relationship. However, specific reduction targets or achievements for Sanofi Medley Farmacêutica Ltda. have not been disclosed. While no absolute emissions figures are provided, the company is aligned with Sanofi's broader climate commitments, which aim to address carbon emissions across all scopes. The lack of specific data highlights the ongoing need for transparency in emissions reporting within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Sanofi Medley Farmacêutica Ltda.'s Industry?
How Carbon Intensive is Sanofi Medley Farmacêutica Ltda.'s Location?
Sanofi Medley Farmacêutica Ltda.'s Scope 3 Categories Breakdown
Sanofi Medley Farmacêutica Ltda.'s Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Top Scope 3 Categories
Sanofi Medley Farmacêutica Ltda.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sanofi Medley Farmacêutica Ltda. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
